Welcome to our dedicated page for Henry Schein news (Ticker: HSIC), a resource for investors and traders seeking the latest updates and insights on Henry Schein stock.
Henry Schein, Inc. (NASDAQ: HSIC) generates a steady flow of news as a FORTUNE 500 and S&P 500® health care solutions company serving office-based dental and medical practitioners. As a medical, dental, and hospital equipment and supplies merchant wholesaler with a significant technology footprint, the company issues updates that cover financial performance, leadership changes, partnerships, and product and technology developments.
Investors following HSIC news will find regular earnings and guidance announcements, including quarterly financial results and updates on sales growth across its Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology segments. These releases often highlight trends in dental and medical distribution, specialty dental products, and technology adoption, as well as commentary on strategic initiatives such as the company’s BOLD+1 strategy and value creation programs.
Henry Schein news also includes leadership and governance updates, such as the announced retirement of long-time CEO Stanley M. Bergman from the chief executive role and the appointment of Frederick M. Lowery as the company’s next CEO, effective March 2, 2026. These items provide insight into succession planning and the company’s approach to long-term leadership continuity.
Another key theme in HSIC coverage is technology and innovation in dental practice management. Through Henry Schein One, the company reports on new AI-enabled workflows, embedded automation, and collaborations with partners like Amazon Web Services and VideaHealth. News items describe developments in practice management platforms such as Dentrix and Dentrix Ascend, including AI-driven documentation, imaging, and revenue cycle tools.
In addition, Henry Schein announces strategic partnerships and distribution agreements, such as its expanded relationship with vVARDIS for the Curodont Repair Fluoride Plus product across U.S. dental segments. These stories shed light on how the company broadens its product offerings and supports dental professionals with new clinical options.
For investors, analysts, and health care professionals, the HSIC news feed on Stock Titan offers a centralized view of these corporate developments, helping users monitor how Henry Schein’s distribution, specialty products, and technology initiatives evolve over time.
Henry Schein (Nasdaq: HSIC) will release its fourth quarter 2025 financial results before the market opens on Tuesday, February 24, 2026.
The company will host a live webcast of its earnings conference call the same day beginning at 8:00 a.m. Eastern. Speakers include Stanley M. Bergman, chairman and CEO, and Ronald N. South, SVP and CFO. Investors can access the live call and a replay via the company's investor webcasts page.
Henry Schein (Nasdaq: HSIC) appointed Frederick M. Lowery as Chief Executive Officer, effective March 2, 2026. Mr. Lowery will join the Board of Directors and succeeds Stanley M. Bergman, who will step down as CEO after 35 years and remain Chairman to support a leadership transition. Mr. Lowery brings more than two decades of healthcare distribution and operations experience, most recently serving as Executive Vice President and President, Laboratory Products and BioProduction at Thermo Fisher (NYSE: TMO). The appointment is presented as alignment with Henry Schein’s BOLD+1 strategic plan and aims to accelerate growth and value creation.
Henry Schein (HSIC) will present at the J.P. Morgan Healthcare Investor Conference on Tuesday, January 13, 2026 at 3:00 p.m. PST / 6:00 p.m. EST at The Westin St. Francis in San Francisco.
Presentations will be available live via webcast at www.henryschein.com/IRwebcasts, with replays posted on the Henry Schein investor website after the event. The company provides health care solutions to office-based dental and medical practitioners.
Henry Schein (Nasdaq: HSIC) said its board expects to appoint the company's next CEO by mid-January 2026. The board described the search as nearing completion after evaluating a pool of highly qualified candidates with exceptional interest and caliber. The company confirmed the decision will not be finalized before year-end and that Stanley Bergman will continue as CEO & Chairman at the board’s request until a successor assumes the role.
The announcement frames a targeted timeline for leadership transition while emphasizing continuity of operations and a planned, orderly handover.
Henry Schein (Nasdaq: HSIC) expanded its agreement with vVARDIS to become the exclusive U.S. distributor of Curodont™ Repair Fluoride Plus across all dental market segments, effective January 1, 2026.
The expanded deal broadens prior 2024 exclusivity for Dental Service Organizations to include general dentistry, orthodontics, and pediatric dentistry nationwide. vVARDIS founders report having accessed over 10% of U.S. dental offices and treated more than 500,000 patients with Curodont. Henry Schein is currently the market leader selling Curodont to general practitioners and DSOs in the U.S. The product offers a drill- and needle-free treatment for early-stage cavities, which the companies describe as an opportunity to increase in-office care for untreated early lesions.
Henry Schein One (NASDAQ:HSIC) unveiled natively embedded AI workflows for Dentrix and Dentrix Ascend at the 2025 Greater New York Dental Meeting (Nov 30–Dec 3, 2025). Key features include Voice Notes for real-time chairside transcription and summaries, Forms that capture insurance data from a photo, Eligibility Pro for real-time benefits, and Detect AI (FDA-cleared) for x‑ray diagnostics. The company also announced Phones integration, a multilingual 24/7 assistant Claire, and plans for predictive scheduling, coding assistants, and unified analytics to improve intake, claims accuracy, and practice efficiency.
Henry Schein (Nasdaq: HSIC) will present at Piper Sandler’s Healthcare Conference on December 2, 2025 at 9:00 a.m. ET at the Lotte New York Palace Hotel in New York.
Investors can listen to the presentation via live webcast at www.henryschein.com/IRwebcasts. Replays will be posted on the Henry Schein investor website after the presentation.
VideaHealth and Henry Schein One (HSIC) launched the Impact Panel, an enhancement to Detect AI that embeds real-time AI findings and patient education directly into Dentrix and Dentrix Ascend imaging workflows on November 5, 2025.
Key features include an interactive odontogram, AI summaries showing tooth damage percentages and bone-level summaries by quadrant, on-screen diagrams, QR codes and print options. The Impact Panel is included at no additional cost for Detect AI users. Practices using the QR feature have reported a 19% increase in case acceptance.
Summary not available.
Henry Schein One (NYSE:HSIC) announced a strategic partnership with AWS to integrate generative AI across its dental platforms, including Dentrix, Dentrix Ascend, and Dentally. The initiative targets AI-native workflows for scheduling, imaging, documentation, claims validation, pricing, and patient engagement to reduce administrative burden and improve outcomes.
The rollout will leverage AWS services such as Amazon Bedrock and Transcribe Medical and aims for global scalability across the U.S., U.K., and E.U. The companies emphasize security, regulatory compliance, and interoperability as core design principles.
FAQ
What is the current stock price of Henry Schein (HSIC)?
What is the market cap of Henry Schein (HSIC)?
